Healthcare workflow technology company Braidio has partnered with health IT vendor BlueSemi with the aim of creating a preventive home-health and telehealth ecosystem.
BlueSemi’s primary product is a handheld device called EYVA, which measures six vitals, including blood glucose, without requiring a pinprick for blood. By integrating the device with Braidio’s My Health Concierge platform, the companies will be attempting to encourage positive behavioral change.
This is the next step from Braidio’s My Health Concierge, which is partnered with other companies, including Arkos Health, AT&T and Etisalat. My Health Concierge contains embedded healthcare workflows, including triggered events and write-back capabilities to major EHRs.
With BlueSemi tracking critical vitals like blood glucose, the two companies now can ensure that healthcare providers have the latest data on the people they care for. Braidio’s remote patient monitoring helps medical professionals get the latest patient data and insights. It is designed to help eliminate barriers that previously prevented ease of access to care.
“Healthcare has been slow to adopt the connectivity that is so prevalent and innovative in other industries,” said Iain Scholnick, CEO of Braidio. “The flow of patient information needs to be completely secure and HIPAA-compliant in order to ensure that doctors can give the best recommendations and provide the best care.
“This level of transparency will deliver healthcare to the future, breaking down the barriers between patients and the highest level of care possible,” he contended.
EYVA leverages sensor fusion, AI and the Internet of Things. The device’s haptic sensors respond to the user’s touch. It can mirror their breathing patterns to eventually measure blood glucose, ECG, heart rate, blood pressure, SpO2 and HbA1c in 60 seconds. No blood is required, because users simply touch the device in the way they touch their phone screens.
Email the writer: [email protected]
Healthcare IT News is a HIMSS Media publication.
Source: Read Full Article